Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference
WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46
Details for the Company’s participation are as follows:
Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET
The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Inflation Meets Expectations as Geopolitical Tensions Cast Shadow on Markets

Can a Shadow Intelligence Firm Win the AI Arms Race?

